Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 12, 2003 - Issue 9
Submit an article Journal homepage
122
Views
40
CrossRef citations to date
0
Altmetric
Review

Challenges and opportunities with glycogen synthase kinase-3 inhibitors for insulin resistance and Type 2 diabetes treatment

Hagit Eldar-Finkelman Department of Human Genetics and Molecular Medicine, Sackler School of Medicine, Ramat Aviv, Tel-Aviv University, Israel. [email protected]
&
Ronit Ilouz Department of Human Genetics and Molecular Medicine, Sackler School of Medicine, Ramat Aviv, Tel-Aviv University, Israel. [email protected]
Pages 1511-1519 | Published online: 02 Mar 2005

Bibliography

  • VIRKAMAKI A, UEKI K, KAHN CR: Protein-protein interaction in insulin signalling and the molecular mechanisms of insulin resistance. I. Clin. Invest. (1999) 103:931–943.
  • SALTIEL AR, PESSIN JE: Insulin signalling pathways in time and space. Trends Cell Biol. (2002) 12:65–71.
  • CROSS DA, ALESSI DR, VANDENHEEDE JR, MCDOWELL HE, HUNDAL HS, COHEN P: The inhibition of glycogen synthase kinase-3 by insulin or insulin-like growth factor-1 in the rat skeletal muscle cell line L6 is blocked by wortmannin but not by rapamycin: evidence that wortmannin blocks activation of the mitogen-activated protein kinase pathway in L6 cells between Ras and Raf. Biochem. (1994) 303:21–26.
  • WELSH GI, PROUD CG: Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukaryotic initiation factor eIF-2B. Biochem. (1993) 294:625–629.
  • MOULE SK, WELSH GI, EDGELL NJ, FOULSTONE EJ, PROUD CG, DENTON RM: Regulation of protein kinase B and glycogen synthase kinase-3 by insulin and beta-adrenergic agonist in rat epididymal fat cells. Biol. Chem. (1997) 272:7713–7719.
  • WOOD GETT JR, COHEN P: Multisite phosphorylation of glycogen synthase. Molecular basis for the substrate specificity of glycogen synthase kinase-3 and casein kinase-II (glycogen synthase kinase-5). Biochim. Biophys. Acta (1984) 788:339–347.
  • WANG Y, ROACH PJ: Inactivation of rabbit muscle glycogen synthase by glycogen synthase kinase-3. Dominant role of the phosphorylation of Ser-640 (site-3a). Biol. Chem. (1993) 268:23876–23880.
  • SHULMAN GI: Cellular mechanisms of insulin resistance in humans. Am. Cardiol (1999) 84:3J–10J.
  • ELDAR-FINKELMAN H, KREBS EG: Phosphorylation of insulin receptor substrate-1 by glycogen synthase kinase-3 impairs insulin action. Proc. Natl. Acad. Sci. USA (1997) 94:9660–9664.
  • TANTI JF, GR'EMEAUX T, VAN OBBERGHEN E, LE MARCHAND-BRUSTEL Y: Serine/ threonine phosphorylation of insulin receptor substrate 1 modulates insulin receptor signalling. J. Biol. Chem. (1994) 269:6051–6057.
  • HOTAMISLIGIL GS, PERALDI P, BUDAVARI A, ELLIS R, WHITE MF, SPIEGELMAN BM: IRS-1 mediated inhibition of insulin receptor tyrosine kinase activity in TNF-a and obesity induced insulin resistance. Science (1996) 271:665–668.
  • NIKOULINA SE, CIARALDI TP, MUDAILAR S, MOHIDEEN P, CARTER L, HENRY RR: Potential role of GSK-3 in skeletal muscle insulin resistance Type 2 diabetes. Diabetes (2000) 49:263–271.
  • •Shows that GSK-3 activity is high in muscle of Type 2 diabetic patients.
  • ELDAR-FINKELMAN H, SCHREYER SA, SHINOHARA MM, LEBOEUF RC, KREBS EG: Increased glycogen synthase kinase-3 activity in diabetes and obesity prone C57BL/6J mice. Diabetes (1999) 48: 1662-1666.
  • HANSEN L, ARDEN K, RASMUSSEN S et al.: Chromosomal mapping and mutational analysis of the coding region of the glycogen synthase kinase-3alpha and beta isoforms in patients with NIDDM. Diabetologia (1997) 40(8):940–946.
  • WOOD GETT JR: cDNA cloning and properties of glycogen synthase kinase-3. Methods Enzymol (1991) 200:564–577.
  • WOODGETT JR: Judging a protein more than its name: GSK-3. ScL STKE (2001) 100:RE12.
  • ••Excellent review on GSK-3.
  • GRIMES CA, JOPE RS: The multifaceted roles of glycogen synthase kinase 3beta in cellular signalling. Frog. Neurobiol (2001) 65:391–426.
  • ••Insightful review on GSK-3.
  • ELDAR-FINKELMAN H: Glycogen synthase kinase-3: an emerging therapeutic target. Trends Ma Med. (2002) 8:126–132.
  • ••This review emphasises the potential roleof GSK-3 as a drug-discovery target.
  • CROSS DA, ALESSI DR, COHEN P, ANDJELKOVICH M, HEMMINGS BA: Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature (1995) 378:785–789.
  • FIOL CJ, MAHRENHOLZ AM, WANG Y, ROESKE RW, ROACH PJ: Formation of protein kinase recognition sites by covalent modification of the substrate. Molecular mechanism for the synergistic action of casein kinase II and glycogen synthase kinase 3. Biol. Chem. (1987) 262:14042–14048.
  • •Shows the unique recognition motif of GSK-3.
  • TER HAAR E, COLL JT, AUSTEN DA, HSIAO HM, SWENSON L, JAIN J: Structure of GSK3I3 reveals a primed phosphorylation mechanism. Nat. Strait. Biol. (2001) 8:593–596.
  • ••Analysis of GSK-3 3D structure.
  • DAJANI R, FRASER E, ROE SM et al: Crystal structure of glycogen synthase kinase 3 beta: structural basis for phosphate-primed substrate specificity and autoinhibition. Cell (2001) 105:721–732.
  • ••Analysis of GSK-3 3D structure.
  • WILLIAMS DD, MARIN 0, PINNA LA, PROUD CG: Phosphorylated seryl and threonyl but not tyrosyl, residues are efficient specificity determinants for GSK-313 and Shaggy. FEBS Lett. (1999) 448:86–90.
  • PLOTKIN B, KAIDANOVICH 0, TALIOR I, ELDAR-FINKELMAN H: Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3. Pharm. Exp. The]: (2003) 305:974–980.
  • •Describes the development of GSK-3 competitive inhibitors and their insulin-like effects in vitro and in vivo.
  • FRASER E, YOUNG N, DAJANI R et al:Identification of the Axin and Frat binding region of glycogen synthase kinase-3. J. Biol. Chem. (2002) 277:2176–2185.
  • RUBINFELD B, ALBERT I, PORFIRI E, FIOL C, MUNEMITSU S, POLAKIS P: Binding of GSK-3 beta to the APC-beta-catenin complex and regulation of complex assembly. Science (1996) 272:1023–1026.
  • FARR GH 3rd, FERKEY DM, YOST C, PIERCE SB, WEAVER C, KIMELMAN D: Interaction among GSK-3, GBP, Axin and APC in Xenopus axis specification. Cell. Biol. (2000) 148:691–702.
  • YOST C, TORRES M, MILLER J, HUANG E, KIMELMAN D, MOON R: The axis-inducing activity, stability and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev. (1996) 10:1443–1454.
  • •Shows the important role of GSK-3 in the regulation of P-catenin.
  • NYFELER F, WALTER P: Effect of lithium59. on glycogen synthesis in hepatocytes from rat liver. FEBS Lett. (1979) 108:197–199.
  • STAMBOLIC V, RUEL L, WOODGETT JR: Lithium inhibits glycogen synthase kinase-3 activity and60.mimics wingless signalling in intact cells. Curr. Biol. (1996) 6:1664–1668.
  • CHENG K, CREACY S, LARNER J: 'Insulin-like' effects of lithium ion on isolated rat adipocytes. I. Stimulation of61.glycogenesis beyond glucose transport. Mol Biochem. (1983) 56:177–182.
  • PEIFER M, PAI LM, CASEY M: Phosphorylation of the Drosophila adherens junction protein Armadillo: roles for wingless signal and zeste-white 3 kinase. Dev. Biol. (1994) 166:543–556.
  • PEIFER M, POLAKIS P: Wnt signaling in oncogenesis and embryogenesis - a look outside the nucleus. Science (2000) 287:1606–1609.
  • •Insightful review of Wnt signaling.
  • THOMAS GM, FRAMES, GOEDERT M, NATHKE I, POLAKIS P, COHEN P: A GSK3-binding peptide from FRAT1 selectively inhibits the GSK3-catalysed phosphorylation of Axin and P-catenin. FEBS Lett. (1999) 458:247–251.
  • TAYLOR SS, KNIGHTON DR, ZHENG J, SOWADSKI JM, GIBBS CS, ZOLLER MJ: A template for the protein kinase family. Trends Biochem. Sci. (1993) 18:84–89.
  • ••Provides the basis for understanding theprotein kinase field.
  • JOHNSON LN, NOBLE ME, OWEN DJ: Active and inactive protein kinases: structural basis for regulation. Cell (1996) 85:149–158.
  • TAYLOR SS, RADZIO-ANDZELM E: Protein kinase inhibition: natural and synthetic variations on a theme. Carr: Opin. Chem. Biol. (1997) 1:219–226.
  • DAVIES SP, REDDY H, CAIVANO M, COHEN P: Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. (2000) 351:95–105.
  • SCAPIN G: Structural biology in drug design: selective protein kinase inhibitors. Drug Discov. Today(2002) 7:601–611.
  • •Good review of new approaches in the design of protein kinase inhibitors.
  • TOLEDO LM, LYDON NB, ELBAUM D: The structure-based design of ATP-site directed protein kinase inhibitors. Curr. Med. Chem. (1999) 6:775–805.
  • •Good review of new approaches in design of protein kinase inhibitors.
  • SOWADSKI JM, EPSTEIN LF, LANKIEWICZ L, KARLSSON R: Conformational diversity of catalytic cores of protein kinases. Pharmacol Ther. (1999) 82:157–164.
  • TRAXLER P, FURET P: Strategies towardthe design of novel and selective protein tyrosine kinase inhibitors. Pharmacol Ther. (1999) 82:195–206.
  • PARANG K, COLE PA: Designing bisubstrate analog inhibitors for protein kinases. Pharmacol Ther. (2002) 93:145–157.
  • RING DB, JOHNSON KW, HENRIKSEN EJ et al.: Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes (2003) 52:588–595.
  • •Reports the insulin-like effect of GSK-3 inhibitors.
  • COGHLAN MP, CULBERT AA, CROSS DA et al.: Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem. Biol. (2000) 7:793–803.
  • •Shows the in vitro and in vivo function of GSK-3 inhibitors.
  • MANJI HM, MOORE GJ, CHEN G: Lithium at 50: have the neuroprotective effects of this unique cation been overlooked? Biol. Psychiatry (1999) 46:929–940.
  • •Insightful review of lithium function.
  • JOPE RS: Antibipolar therapy: mechanism of action of lithium. Mol Psych. (1999) 4:117–128.
  • KLEIN PS, MELTON DA: A Molecular Mechanism for the Effect of Lithium on Development. Proc. Natl. Acad. Sci. USA (1996) 93:8455–8459.
  • •Reports lithium as a GSK-3 inhibitor.
  • RYVES WJ, HARWOOD AJ: Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem. Biophys. Res. Comm. (2001) 280:720–725.
  • CHENG K, CREACY S, LARNER J: 'Insulin-like' effects of lithium ion on isolated rat adipocytes. II. Specific activation of glycogen synthase. Ma Cell. Biochem. (1983) 56:183–189.
  • ORENA SJ, TORCHIA AJ, GAROFALO RS: Inhibition of GSK-3 stimulates glycogen synthase and glucose transport by distinct mechanisms in 3T3-L1 adipocytes. Biol. Chem. (2000) 275:15765–15772.
  • RYVES WJ, DAJANI R, PEARL L, HARWOOD AJ: Glycogen synthase kinase-3 inhibition by lithium and beryllium suggests the presence of two magnesium binding sites. Biochem. Biophys. Res. Comm. (2002) 290:967–972.
  • ILOUZ R, KAIDANOVIDH 0, GURWITZ D, ELDAR-FINKELMAN H: Inhibition of glycogen synthase kinase-3b by bivalent zinc ions: insight into the insulin-mimetic action of zinc. Biochem. Biophys. Res. Commun. (2002) 295:102–106.
  • COULSTON L, DANDONA P: Insulin-like effect of zinc on adipocytes. Diabetes (1980) 29:665–667.
  • MAY JM, CONTOREGGI CS: The mechanism of the insulin-like effects of ionic zinc. Biol. Chem. (1982) 257:4362–4368.
  • EZAKI 0: IIb group metal ions (Zn2+, Cd2+, Hg2+) stimulate glucose transport activity by postinsulin receptor kinase mechanism in rat adipocytes. Biol. Chem. (1989) 264:16118–16222.
  • SIMON SF, TAYLOR CG: Dietary zinc supplementation attenuates hyperglycemia in db/db mice. Exp. Biol. Med. (2001) 226:43–51.
  • LECLERC S, GARNIER M, HOESSEL R et al.: Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? I Biol. Chem. (2001) 276:251-260. LEOST M, SCHULTZ C, LINK A et al.: Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. Ear: I Biochem. (2000) 267:5983-5994. PAP M, COOPER G: Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-Kinase/Akt cell survival pathway. J. Biol. Chem. (1998) 273:19929–19932.
  • BIJUR GN, DE SARNO P, JOPE RS: Glycogen synthase kinase-3 beta facilitates staurosporine- and heat shock-induced apoptosis. Protection by lithium. Biol. Chem. (2000) 275:7583-7590. Report the pro-apoptotic feature of GSK–3.
  • RUBINFELD B, ROBBINS P, EL-GAMIL M, ALBERT I, PORFIRI E, POLAKIS P: Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science (1997) 25:1790–1792.
  • LOCHHEAD PA, COGHLAN M, RICE SQ, SUTHERLAND C: Inhibition of GSK-3 selectively reduces glucose-6-phosphatase and phosphatase and phosphoenolypyruvate carboxykinase gene expression. Diabetes (2001) 50:937–946.
  • WITHERINGTON J, BORDAS V, HAIGH D et al.: 5-Aryl- pyrazolo [3,4-blpyridazines: potent inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg. Med. Chem. Lett. (2003) 13:1581–1584.
  • NIKOULINA SE, CIARALDI TP, MUDALIAR S, CARTER L, JOHNSON K, HENRY RR: Inhibition of glycogen synthase kinase 3 improves insulin action and glucose metabolism in human skeletal muscle. Diabetes (2002) 51:2190–2198.
  • •Reports the insulin-like effect of GSK-3 inhibitors.
  • HENRIKSEN EJ, KINNICK TR, TEACHEY MK et al.: Modulation of muscle insulin resistance by selective inhibition of GSK-3 in Zucker diabetic fatty rats. Am.,/ Physiol. Endocrinol. Metab. (2003) 284:E892–E900.
  • •Reports the in vivo insulin-like effect of GSK-3 inhibitors.
  • CLINE GW, JOHNSON K, REGITTNIG W et al.: Effects of a novel glycogen synthase kinase-3 inhibitor on insulin-stimulated glucose metabolism in Zucker diabetic fatty (fa/fa) rats. Diabetes (2002) 51:2903–2910.
  • •Reports the in vivo insulin-like effect of GSK-3 inhibitors.
  • VX-608. IDdb3 Drug Report (2003).
  • KINETEK: GSK-313 inhibitors. IDdb3 Drug Report (2002).
  • NAERUM L, NORSKOV- LAURITSEN L, OLESEN PH: Scaffold hopping and optimization towards libraries of glycogen synthase kinase-3 inhibitors. Bioorg. Med. Chem. Lett. (2002) 12:1525–1528.
  • NOVO NORDISK: GSK-3 inhibitors. IDdb3 Drug Report (2002).
  • MARTINEZ A, ALONSO M, CASTRO A, PEREZ C, MORENO FJ: First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. I Med. Chem. (2002) 45:1292–1299.
  • LINDSAY MA: Peptide-mediated cell delivery: application in protein target validation. Carr. Opin. Pahrmacol. (2002) 2:587–594.
  • HAWIGER J: Noninvasive intracellular delivery of functional peptides and proteins. Carr. Opin. Chem. Biol. (1999) 3:89–94.
  • HEINEMANN L, PFUTZNER A, HEISE T: Alternative routes of administration as an approach to improve insulin therapy: update on dermal, oral, nasal and pulmonary delivery. Carr: Pharm. Des. (2001) 14:1327–1351.
  • SENEL S, KREMER M, NAGY K, SQUIER C: Delivery of bioactive peptides and proteins across oral (buccal) mucosa. Carr. Pharm. Biotechnol. (2001) 2:175–186.
  • DENNIS MS, ZHANG M, MENG YG et al.: Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J. Biol. Chem. (2002) 277:35035–35043.
  • MARKUSSEN J, HAVELUND S, KURTZHALS P et al.: Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia (1996) 39:281–288.
  • WAKEFIELD JG, STEPHENS DJ, TAVARE JM: A role for glycogen synthase kinase-3 in mitotic spindle dynamics and chromosome alignment. Cell Sci. (2003) 116:637–646.
  • HOEFLICH KP, LUO J, RUBIE EA, TSAO MS, JIN 0, WOOD GETT JR: Requirement for glycogen synthase kinase-3I3 in cell survival and NF-icB activation. Nature (2000) 406:86–90.
  • WENTE SR, VILLALBA M, SCHRAMM VL, ROSEN OM: Mn2H- binding properties of a recombinant protein-tyrosine kinase derived from the human insulin receptor. Proc. Nati Acad. Sci. USA (1990) 87:2805–2809.
  • WANG QM, PARK IK, FIOL CJ, ROACH PJ, DEPAOLI-ROACH AA: Isoform differences in substrate recognition by glycogen synthase kinases 3 alpha and beta in the phosphorylation of phosphatase inhibitor 2. Biochemistry (1994) 33:143–147.
  • VERTEX: IDdb3 report (2003).

Website

  • http://EnvironmentalChemistry.com Environmental, chemistry and hazardous materials and resources.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.